RESPONSE TO OLUTASIDENIB IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) FOLLOWING VENETOCLAX FAILURE

EHA Library, Jorge Cortes, 420678

REAL-WORLD EXPERIENCE USING CPX-351 FOR AML-MRC AND THERAPY RELATED MYELOID NEOPLASMS.

EHA Library, Daniele Avenoso, 420679

IMPACT OF PREVIOUS CHEMOTHERAPY (CT) EXPOSURE ON  MOLECULAR CHARACTERISTICS AND TREATMENT OUTCOMES OF THERAPY RELATED MYELOID NEOPLASMS (T-MN)

EHA Library, Pinkal Desai, 420681

PRESENCE OF BONE MARROW FIBROSIS AND NECROSIS IS ASSOCIATED WITH INFERIOR OVERALL SURVIVAL IN NPM1-MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Elliot Smith, 420682

COMPARING OUTCOMES BETWEEN CPX-351 AND FLUDARABINE-BASED INDUCTION IN SECONDARY OR THERAPY RELATED ACUTE MYELOID LEUKEMIA: THE PROGNOSTIC ROLE OF MRD

EHA Library, Chiara Vernarecci, 420683

PROGNOSTIC FACTORS IN TP53-MUTATED AML/MDS PATIENTS UNDERGOING ALLO-HSCT: INSIGHTS FROM A MULTI-CENTER STUDY

EHA Library, Yanmin Zhao, 420685

BURDEN OF ACUTE LEUKEMIAS AND MYELODYSPLASTIC SYNDROMES IN A LARGE OBSERVATIONAL STUDY (ILL-CAR-2018-01) ON LONG-TERM BREAST CANCER SURVIVORS

EHA Library, Jorge Illarramendi Esteban, 420686

REDUCED DOSE FLAG-MITOXANTRONE AND LOW DOSE VENETOCLAX INDUCES DEEP REMISSIONS AND HIGH RATE OF TRANSITION TO SUCCESSFUL ALLOGENEIC STEM CELL TRANSPLANTATION INRELAPSED/REFRACTORY AML

EHA Library, Ahmad Ibrahim, 420687

EFFICACY OF VENETOCLAX IN COMBINATION WITH STANDARD INTENSIVE (3+7) INDUCTION IN ADULT ACUTE MYELOID LEUKEMIA – EARLY RESULTS FROM A REAL-WORLD EXPERIENCE.

EHA Library, Akash Kumar, 420688

BASELINE GENOMIC TESTING AND OVERALL SURVIVAL IN PATIENTS WITH ACUTE MYELOID LEUKEMIA IN THE MODERN ERA: REAL-WORLD DATA FROM A LARGE US COHORT

EHA Library, Xin Wang, 420689

CLINICAL OUTCOMES OF CONCURRENT FLT3 INHIBITOR AND IDH INHIBITOR THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Catherine Gutierrez Moore, 420690

CHEMOTHERAPY-FREE CONSOLIDATION IS EQUALLY EFFECTIVE AS CHEMOTHERAPY-INCLUSIVE APPROACHES IN HIGH-RISK APL PATIENTS POST-REMISSION INDUCTION

EHA Library, Fangyi Dong, 420691

RICHTER SYNDROME DIFFUSE LARGE B-CELL LYMPHOMA TYPE: PHENOTYPIC CHARACTERIZATION AND COMPARATIVE ANALYSIS WITH THE ORIGINAL CLL AND WITH DE NOVO DIFFUSE LARGE B-CELL LYMPHOMAS

EHA Library, Fernando Martin Moro, 420692

ACSL1 PROMOTES FERROPTOSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA VIA DUSP6/ERK PATHWAY

EHA Library, Xin Wang, 420693

ASSOCIATION BETWEEN GENOMIC ALTERATIONS AND SERUM MONOCLONAL PROTEINS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Juan Antonio Pineyroa Gigosos, 420694

FOXO1-MEDIATED CELL CYCLE ARREST AND APOPTOSIS IS INHIBITED BY USP7 DOWNSTREAM OF BCR LIGATION IN CLL CELLS.

EHA Library, Hassan Almuhanna, 420695

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) PATIENT DEMOGRAPHICS AND PATIENT-REPORTED BURDEN IN IBRUTINIB AND NON-IBRUTINIB RECEIVERS IN THE US: A REAL-WORLD STUDY.

EHA Library, Zaina Qureshi, 420696

ADVANCED CYTOGENOMIC APPROACHES FOR PRECISE RECONSTRUCTION OF COMPLEX KARYOTYPE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Sabina Adamová, 420697

EXPLORING THE RELATIONSHIP BETWEEN KARYOTYPE COMPLEXITY AND DNA METHYLATION IN UNMUTATED IGHV CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Stella Charalampopoulou, 420698

A CX3CR1 (FRACTALKINE RECEPTOR) SMALL MOLECULE ANTAGONIST (KAND567) SUPPRESSED THE GROWTH-PROMOTING EFFECT OF NURSE-LIKE CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Wen Zhong, 420699

JAK3-STAT5 SIGNALING IS INVOLVED IN SHAPING THE IMMUNE INHIBITORY PHENOTYPE OF T HELPER CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Shimrit Ringelstein-Harlev, 420700

RESISTANCE MECHANISMS ASSOCIATED TO ONE-CARBON METABOLISM INHIBITION IN B-CELL MALIGNANCIES

EHA Library, Chloé Duculty, 420701

BIOENGINEERED SMALL EXTRACELLULAR VESICLES AS INNOVATIVE IMMUNOTHERAPIES IN CLL

EHA Library, Lucie Rospape, 420702

GLUTAMINE ADDICTION IN THE CLL MICROENVIRONMENT; TOWARDS IMPROVED DETECTION WITH PET IMAGING

EHA Library, Helga Simon-Molas, 420703

PREVALENCE AND CLINICAL IMPACT OF CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Samir Mouhssine, 420704

FUNCTIONAL PHENOTYPE MODEL PREDICTS PROGRESSION FREE SURVIVAL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON141/VISION TRIAL

EHA Library, Weikaixin Kong, 420705

PRELIMINARY ANALYSIS OF THE COMPLEX PROJECT: IMPACT OF GENOMIC COMPLEXITY IN CLL PATIENTS TREATED WITH TARGETED THERAPIES IN A REAL-LIFE SETTING

EHA Library, Silvia Ramos-Campoy, 420706

IMMUNE CELL EFFECTS OF LONG-TERM ACALABRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Olina Lind, 420707

ΝON-MUTATIONAL MYC ACTIVATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: FROM TRANSCRIPTOMICS TO CLINICOBIOLOGICAL ASSOCIATIONS

EHA Library, Maria Tsagiopoulou, 420708

SINGLE-CELL SEQUENCING OF IN VITRO 3D CLL MODEL PROVIDE INSIGHT INTO INTERACTIONS WITHIN THE CLL LYMPH NODE NICHE UPON TREATMENT WITH BTK INHIBITORS

EHA Library, Marco Haselager, 420709

ANALYSIS OF MUTATIONS IN BTK AND BCL2 WITH CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS SUGGESTS DIFFERENT RESISTANCE MECHANISMS AND SUBCLONAL DYNAMICS UNDER TREATMENT WITH BTK OR BCL2 INHIBITORS

EHA Library, Miguel Bastos Boente, 420710

DIETARY INFLUENCES ON CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION: UNVEILING THE POTENTIAL OF EARLY-STAGE INTERVENTION

EHA Library, Maike Buchner, 420711

LIVE CLL CELLS INSIDE THE BONE MARROW FIBROBLASTS AND ITS IMPLICATION IN DISEASE PERSISTENCE

EHA Library, Y. Lynn Wang, 420712

DYNAMIC STIMULATION PROMOTES FUNCTIONAL TISSUE-LIKE ORGANISATION OF A 3D HUMAN LYMPHOID MICROENVIRONMENT MODEL AND ALLOWS TO STUDY CLL CELLS TRAFFICKING IN VITRO

EHA Library, Dafne Barozzi, 420713

MUTATIONAL STATUS OF KAPPA AND LAMBDA LIGHT CHAIN GENES INDEPENDENTLY PREDICTS TIME TO FIRST TREATMENT IN EARLY-STAGE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jana Nabki, 420714

REAL-WORLD USE AND EFFECTIVENESS OF ACALABRUTINIB IN CHRONIC LYMPHOCYTIC LEUKAEMIA: THE NATIONAL ACALABRUTINIB OBSERVATIONAL STUDY (NAOS)

EHA Library, Anne Quinquenel, 420715

REAL LIFE EVIDENCE OF THE USE OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A REGISTRY STUDY ON BEHALF OF THE SPANISH CLL GROUP (GELLC)

EHA Library, Alberto Lopez García, 420716

PRELIMINARY SAFETY AND EFFICACY RESULTS FROM A PHASE 1B STUDY OF ORAL NON-COVALENT BTK INHIBITOR AS-1763 IN PATIENTS WITH PREVIOUSLY TREATED B-CELL MALIGNANCIES

EHA Library, Nitin Jain, 420717

REAL-WORLD OUTCOME OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED WITH BTK INHIBITORS (BTKI): A SUBGROUP ANALYSIS OF OVER 1100 PATIENTS ENROLLED INTO THE GIMEMA CLL2121 STUDY

EHA Library, Lydia Scarfò, 420718

PHASE I TRIAL OF A PERSONALIZED MULTI-PEPTIDE VACCINE COMBINED WITH THE TLR1/2 LIGAND XS15 UNDER BRUTON-TYROSINE-KINASE INHIBITOR (BTKI) TREATMENT IN CLL PATIENTS

EHA Library, Susanne Jung, 420719

PIRTOBRUTINIB IN RELAPSED/REFRACTORY CLL/SLL: RESULTS FROM BTKI NAÏVE COHORT IN THE PHASE 1/2 BRUIN STUDY

EHA Library, Toby Eyre, 420720

TARGETED THERAPIES ERADICATE THE NEGATIVE PROGNOSTIC IMPACT OF IGHV SUBSET#2 IN CHRONIC LYMPHOCYTIC LEUKEMIA : A RETROSPECTIVE REAL-LIFE MULTICENTER FRENCH STUDY

EHA Library, Lucile Bussot, 420721

TIME TO NEXT TREATMENT AFTER FIRST-LINE TREATMENT WITH TIME-LIMITED TARGETED AGENTS: A POOLED ANALYSIS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITHIN CLINICAL TRIALS OF THE GCLLSG

EHA Library, Nadine Kutsch, 420722

REAL-WORLD CARDIOVASCULAR AND CLINICAL OUTCOMES IN PATIENTS INITIATING COVALENT BTK INHIBITORS (CBTKI) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE UNITED STATES

EHA Library, Hayden Hyatt, 420723

A CLINICAL PHASE II STUDY ON INTERMITTENT AND REPEATED DOSING (“ON-OFF-REPEAT”) OF IBRUTINIB TREATMENT FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Jeanette Lundin, 420724

IMPACT OF VENETOCLAX-BASED THERAPIES ON AUTOIMMUNE CYTOPENIAS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER STUDY CONDUCTED BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL

EHA Library, Marta Coscia, 420725

FEASIBILITY OF VENETOCLAX-BASED REGIMENS IN 110 OCTOGENARIAN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: A RETROSPECTIVE MULTICENTER ITALIAN STUDY

EHA Library, andrea serafin, 420726

SECOND LINE TREATMENT WITH BRUTON TYROSINE KINASE INHIBITOR (BTKI) OR BCL-2 INHIBITOR (BCL-2I) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRIMARY ANALYSIS OF THE CZECH STUDY GROUP FOR CLL (CSCLL)

EHA Library, Jana Mihályová, 420727

FIRST LINE (1L) IBRUTINIB (IBR) IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) DEMONSTRATES OVERALL SURVIVAL (OS) COMPARABLE TO AN AGE-MATCHED EUROPEAN POPULATION

EHA Library, Paolo Ghia, 420728

REAL-WORLD TREATMENT EFFECTIVENESS IN HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING VENETOCLAX-BASED THERAPY: AN INTERNATIONAL STUDY

EHA Library, Catherine C. Coombs, 420729

EFFICACY OF PEMBROLIZUMAB MONOTHERAPY AND IN COMBINATION WITH BCR INHIBITORS FOR RICHTER TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Yucai Wang, 420730

IBRUTINIB LEAD-IN FOLLOWED BY VENETOCLAX PLUS IBRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Davide Rossi, 420731

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT (CNSI)

EHA Library, Mariia Mikhaleva, 420732

SAFETY AND EFFICACY OF LP-108, A NOVEL AND SELECTIVE BCL-2 INHIBITOR, IN CHINESE PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA FROM A PHASE I STUDY

EHA Library, Wei Xu, 420733

FINAL ANALYSIS OF THE RESONATE-2 STUDY: UP TO 10 YEARS OF FOLLOW-UP OF FIRST-LINE IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA

EHA Library, Jan Burger, 420734

REAL-WORLD TREATMENT EFFECTIVENESS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING VENETOCLAX-BASED THERAPY AFTER BRUTON TYROSINE KINASE INHIBITORS: AN INTERNATIONAL STUDY

EHA Library, Nilanjan Ghosh, 420735

A PHASE 2 STUDY OF MINIMAL RESIDUAL DISEASE (MRD)-ADAPTED, TIME-LIMITED ACALABRUTINIB AND OBINUTUZUMAB FOR THE INITIAL TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): MRD OUTCOMES

EHA Library, Lindsey Roeker, 420736

CLINICAL IMPACT OF CLONAL RELATIONSHIP IN RICHTER TRANSFORMATION: AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC

EHA Library, Riccardo Moia, 420737

OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA THAT FAILED BTK INHIBITOR AND VENETOCLAX-BASED TREATMENTS, AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC

EHA Library, Thomas Chatzikonstantinou, 420738

OUTCOMES IN HIGH-RISK SUBGROUPS AFTER FIXED-DURATION IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: UP TO 5.5 YEARS OF FOLLOW-UP IN THE PHASE 2 CAPTIVATE STUDY

EHA Library, Ryan Jacobs, 420739

HOW WELL ARE OUR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA?

EHA Library, Claire Hutchinson, 420740

UPTAKE OF THE FIRST TO FIFTH DOSES OF COVID-19 VACCINE IN INDIVIDUALS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA: A NATIONWIDE COHORT STUDY IN SWEDEN

EHA Library, Lisa Blixt, 420741

A PATIENT PERSPECTIVE ON BEING TOLD THEY HAVE A NEW DIAGNOSIS OF CLL: RESULTS OF AN ONLINE SURVEY IN THE UK

EHA Library, Renata Walewska, 420742

CENTRAL NERVOUS SYSTEM INVOLVEMENT IN CLL. AN INTERNATIONAL MULTICENTER STUDY CONDUCTED BY ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL

EHA Library, Maya Koren-Michowitz, 420743

ORELABRUTINIB, FLUDARABINE, CYCLOPHOSPHAMIDE, AND OBINUTUZUMAB (OFCG) FOR FIRST-LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTICENTER, INVESTIGATOR-INITIATED STUDY (CWCLL-001 STUDY)

EHA Library, Huayuan Zhu, 420744

LONG TERM FOLLOW-UP OF HAIRY CELL LEUKEMIA TREATMENT: 30-YEAR EXPERIENCE AT SINGLE UNIVERSITY CENTER

EHA Library, Jelena Ivanović, 420745

RETREATMENT WITH VENETOCLAX AND RITUXIMAB COMBINATION FOLLOWING DISEASE PROGRESSION WHILE OFF THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Danielle M. Brander, 420746

SF3B1 MUTATION PREDICTS SHORTENED SURVIVAL IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TREATED WITH IBRUTINIB

EHA Library, Anna Petráčková, 420747

INTERIM RESULTS FROM ASSURE: A PHASE 3B SAFETY STUDY OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Stephen Opat, 420748

REAL-WORLD BRUTON TYROSINE KINASE INHIBITOR TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA IN US COMMUNITY ONCOLOGY PRACTICES

EHA Library, Jing-Zhou Hou, 420749

ANALYSIS OF CLINICAL OUTCOMES OF THE CONSERVATIVE APPROACH IN TREATMENT INDICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHTS FROM THE BRAZILIAN REGISTRY OF CLL

EHA Library, Celso Arrais-Rodrigues, 420750

ALLOGENIC TRANSPLANTATION IN CHRONIC LYMPHOCYTIC LEUKEMIA IN A SINGLE CENTER: 10 YEARS FOLLOW-UP AND FOCUS ON BTKI/BCL2I DOUBLE EXPOSED CLL

EHA Library, Thérèse Aurran, 420751

PROGNOSTIC RELEVANCE OF THE IMMUNOGLOBULIN LIGHT CHAIN REARRANGEMENT IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Mischa Vervoordeldonk, 420752

THE ENDOTHELIAL ACTIVATION AND STRESS INDEX (EASIX) INDEPENDENTLY PREDICTS TIME TO FIRST TREATMENT IN CLL, WHILE ITS IMPACT ON PFS SEEMS TO DEPEND ON THE TREATMENT STRATEGY

EHA Library, Pablo Mozas, 420753

PROGRESSION ON COVALENT BRUTON TYROSINE KINASE INHIBITORS PREDICTS POOR OUTCOMES IN CBTKI-EXPOSED AND CBTKI-VENETOCLAX DOUBLE-EXPOSED POPULATIONS: A RETROSPECTIVE FILO STUDY IN 154 R/R CLL PATIENTS

EHA Library, Loïc Ysebaert, 420754

IMPACT OF FIRST-YEAR DOSE MODIFICATIONS OF ACALABRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Alessandra Tedeschi, 420755

SCOPING OUT CARDIOVASCULAR ASSESSMENT ON INITIATION AND SUBSEQUENT MONITORING DURING BTKI THERAPY, AN ERIC INITIATIVE

EHA Library, Thomas Chatzikonstantinou, 420756

INCIDENTAL LYMPHADENOPATHY AND SPLENOMEGALY ON IMAGING STUDIES CAN PREDICT TIME TO FIRST CLL THERAPY AND OVERALL SURVIVAL IN PATIENTS WITH CLL-LIKE HIGH COUNT MONOCLONAL B-CELL LYMPHOCYTOSIS

EHA Library, Samuel Kosydar, 420757

COMPARATIVE EFFECTIVENESS OF IBRUTINIB FLEXIBLE DOSING TREATMENT STRATEGIES ON TIME TO NEXT TREATMENT IN A LARGELY COMMUNITY-BASED CLAIMS DATABASE: A TARGET TRIAL EMULATION STUDY

EHA Library, Nilanjan Ghosh, 420758

POT1 MUTATIONS IDENTIFY INFERIOR OUTCOMES IN CHRONIC LYMPHOCYTIC LEUKEMIA AND DISRUPTED TELOMERE BIOLOGY FUNCTION

EHA Library, Bihui Pan, 420759

COMPARISON OF TIME TO NEXT TREATMENT BETWEEN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA INITIATING FIRST-LINE IBRUTINIB OR ACALABRUTINIB OVERALL AND IN A SUBGROUP WITH HIGH-RISK CHARACTERISTICS

EHA Library, Ryan Jacobs, 420760

REAL-WORLD TREATMENT SWITCHING AND SEQUENCING TO NEXT LINE OF THERAPY OF ZANUBRUTINIB, ACALABRUTINIB, AND IBRUTINIB IN CLL/SLL

EHA Library, Javier Pinilla-Ibarz, 420761

ZANUBRUTINIB VS OTHER BRUTON’S TYROSINE KINASE INHIBITORS IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A MULTILEVEL NETWORK META-REGRESSION

EHA Library, Mazyar Shadman, 420762

6-YEAR TIME TO NEXT TREATMENT (TTNT) EXTRAPOLATION CURVE FOR GLOW STUDY: FIRST-LINE IBRUTINIB + VENETOCLAX (I+V) OFFERS LONG TREATMENT-FREE PERIOD FOR ELDERLY/UNFIT CLL PATIENTS

EHA Library, Santiago Ossorio Prendes, 420763

EFFICACY OF ZANUBRUTINIB VERSUS ACALABRUTINIB IN THE TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (R/R CLL): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Mazyar Shadman, 420764

COMPARATIVE EFFICACY OF BRUTON TYROSINE KINASE INHIBITORS IN THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: A NETWORK META-ANALYSIS

EHA Library, Mazyar Shadman, 420765

EFFICACY AND SAFETY OF ZANUBRUTINIB VS. VENETOCLAX+IBRUTINIB IN THE TREATMENT-NAÏVE (TN) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC)

EHA Library, Talha Munir, 420766

IMPACT OF ACALABRUTINIB TREATMENT BY LINE OF THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: POOLED ANALYSIS FROM ELEVATE-TN, ELEVATE-RR, AND ASCEND

EHA Library, Paolo Ghia, 420767

IBROMICS: A REAL-WORLD STUDY OF CLINICAL AND BIOLOGICAL PARAMETERS DETERMINING RESPONSE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) TREATED IN FIRST LINE WITH SINGLE AGENT IBRUTINIB.

EHA Library, JOSE ANGEL HERNANDEZ RIVAS, 420768

C3G DEFICIENCY DELAYS CHRONIC MYELOID LEUKEMIA DEVELOPMENT IN A P210 BCR-ABL1 TRANSGENIC MODEL

EHA Library, Pablo Berrocal Navarro, 420769

DESIGN AND VALIDATION OF A MASS CYTOMETRY APOPTOTIC PANEL FOR PREDICTING SENSITIVITY OF CHRONIC MYELOID BLAST CELLS CROSS-RESISTANT TO TYROSINE KINASE INHIBITORS TO THE BCL2 INHIBITOR VENETOCLAX

EHA Library, Adam Laznicka, 420770

MAKING TKI DISCONTINUATION MORE EFFICIENT IN CHRONIC MYELOID LEUKEMIA: THE ROLE OF CIRCULATING CYTOKINES AND RESIDUAL PRIMITIVE LEUKEMIC CELLS.

EHA Library, Michele Bianchini, 420771

MODELING SRSF2/TET2 MUTATIONAL COOPERATIVITY IN CMML DEVELOPMENT

EHA Library, Dina Alihodzic, 420773

KF-1601, A DUAL INHIBITOR BCR::ABL1 AND FLT3, OVERCOMES DRUG RESISTANCE IN FLT3+ BLAST PHASE CHRONIC MYELOGENOUS LEUKEMIA

EHA Library, Sung-Min Ahn, 420774

UPDATE OF THE FRENCH STOP IMATINIB STUDY (STIM1) EXTENDED LONG TERM FOLLOW UP.

EHA Library, François-Xavier Mahon, 420776

EUROPEAN LEUKEMIANET MILESTONES AND THEIR PROGNOSTIC RELEVANCE FOR ACHIEVING DEEP MOLECULAR RESPONSE AND TREATMENT-FREE REMISSION IN ROUTINE CARE: RESULTS OF THE GERMAN CML REGISTRY

EHA Library, Katharina Kohlbrenner, 420777

TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 657 ITALIAN PATIENTS

EHA Library, Valentina Bonuomo, 420778

DEEP MOLECULAR RESPONSE RATE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA. ELIGIBILITY TO DISCONTINUATION RELATED TO TIME TO RESPONSE AND DIFFERENT FRONTLINE TKI: THE LABNET CML NATIONAL NETWORK

EHA Library, Massimo Breccia, 420779

IMPROVEMENT OF TREATMENT-FREE REMISSION RATE FOLLOWING DISCONTINUATION OF BCR::ABL1 TKI WITH A FASTER INITIAL DECLINE OF BCR::ABL1 TRANSCRIPT AND LONGER TREATMENT DURATION IN CHRONIC MYELOID LEUKEMIA

EHA Library, SEWON LEE, 420780

ONE YEAR ANALYSIS OF GROWTH DATA IN NEWLY-DIAGNOSED PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH BOSUTINIB: RESULTS FROM TRIAL ITCC-054/COG-AAML1921

EHA Library, Edoardo Pennesi, 420781